Tag: Immunotherapy

Adjuvant PD-1/PD-L1 Inhibitors Show Efficacy but Highlight Safety Considerations in Solid Cancers

April 7, 2026

“Programmed cell death protein-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitors are widely used in cancer treatment.” BUFFALO, NY - April 7, 2026 – A new research paper was published… read more

Oncotarget

Engineered Bacterial Therapy Activates Immune Response in Cancer Preclinical Studies

October 8, 2025

“ACTM-838 showed durable anti-tumor efficacy in multiple murine tumor models and synergized with anti-PD1 therapy in combination.” BUFFALO, NY - October 8, 2025 – A new research paper was published… read more

Oncotarget

CHEK2 Identified as a Potential Target to Improve Immunotherapy in Solid Tumors

June 20, 2025

“Taken together, CHEK2 expression has the potential to predict resistance or non-response to immunotherapy.” BUFFALO, NY - June 20, 2025 – A new review was published in Volume 16 of… read more

Oncotarget

Rare Pancreatic Cancer Patients Show Strong Response to Immunotherapy

June 17, 2025

“Our case series adds to published data from early-phase trials supporting the promise of immunotherapy in some patients with PC.” BUFFALO, NY - June 17, 2025 – A new research… read more

Oncotarget

Immune Side Effects of Liver Cancer Therapy Studied in Latin American Patients

May 23, 2025

“This study provides valuable insights into the incidence and impact of irAEs in patients with HCC treated with the combination of atezolizumab and bevacizumab in real-world practice.” BUFFALO, NY -… read more

Oncotarget

Combining Radiation and Immunotherapy Shows Promise for Bladder Cancer

May 21, 2025

"The synergistic mechanisms of radiation therapy and immunotherapy have demonstrated significant potential for enhancing the outcomes of cancer treatment." BUFFALO, NY - May 21, 2025 – A new review was… read more

Oncotarget

Clear Scans Can Be Misleading: Residual Cancer Linked to Worse Outcomes

March 21, 2025

"SABR is a well-established therapy in both the curative and metastatic setting, however, its ablative potential may not be as high as suggested by radiographic local control rates.” BUFFALO, NY… read more

Oncotarget

Anti-Correlation Between KLRG1 and PD-1 in Tumor CD8 T Cells

January 21, 2025

“The anti-correlation of PD-1 and KLRG1 expression in human tumor infiltrating CD8 T cells suggests the potential for combination therapy supra-additive benefits of anti-PD-1 and anti-KLRG1 therapies.” BUFFALO, NY -… read more

Oncotarget

Mesenchymal Stem Cells in Cancer Immunotherapy: Promises and Challenges

December 3, 2024

“MSCs hold great promise as a therapeutic tool in cancer immunotherapy due to their immunomodulatory properties, tumor-homing abilities, and potential as carriers for delivering therapeutic agents.” BUFFALO, NY - December… read more

Oncotarget

Immunotherapy Success in KRAS G12C Adenosquamous Pancreatic Cancer

November 4, 2024

“Here, we present a case of metastatic ASCP with a KRAS G12C mutation refractory to multiple lines of systemic therapy, including platinum-based chemotherapy and targeted inhibition of KRAS G12C.” BUFFALO,… read more